\
&
Contact us
\
&
Contact us
This was 11 months ago
LocationBerlin, Germany
ProgrammesThe first EP PerMed Conference on 11 and 12 February will provide an international forum for up to 400 participants to present and discuss research and methodologies in various fields supporting the development of personalised medicine approaches. The event is an opportunity for experts in the field to create new connections and research networks.
Back-to-back with the conference, EP PerMed is organising a training workshop on “Training on Scientific Integrity” on 12 and 13 February. The number of participants to the training workshop is limited. Register on the event's webpage.
More information on the conference and registration on the EP PerMed website.
Background: The European Partnership for Personalised Medicine (EP PerMed) brings together European as well as international, national and regional ministries and funding organisations, agencies and authorities, joining forces on several levels and sectors. To realise the full potential of personalised medicine (PM), EP PerMed supports the entire PM value continuum by a wide range of definite actions, including joint research funding and supporting activities among others.
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
The Horizon2020 project BEAT-AF brings together 9 European renowned clinical centres in France, Belgium, Czechia, Germany and Austria. Together, the consortium strives to revolutionize Atrial Fibrillation (AF) treatment through catheter ablation and contribute to decrease the huge burden of AF in Europe. The BEAT-AF project kicked off in 2021 and will run until 2026. The department of electrophysiology of the AZ Sint-Jan Hospital in Bruges is partner in the project and has so far contributed to the pre-clinical development, the first in man studies and first registries of the revolutionary AF treatment put forward by the consortium. The first pilot studies show that the treatment is safe, effective and efficient.
